
Immunovant Inc (IMVT) Stock Forecast & Price Target
Immunovant Inc (IMVT) Analyst Ratings
Bulls say
Immunovant Inc. has demonstrated a strong potential for its candidate IMVT-1402, evidenced by a sustained reduction in TRAb levels throughout the off-treatment period, which indicates the disease-modifying capabilities of FcRn blockers in Graves' disease. The company reported a remarkable responder rate of 81% in patients during the six-month off-treatment phase, paralleling the 70%-80% responder rates observed during active treatment. This data not only highlights the efficacy of its treatment but also instills confidence in the durability of effects in a population previously unresponsive to existing therapies, reinforcing the positive outlook for the company's future.
Bears say
Immunovant Inc is currently engaged in the development of IMVT-1402 to address autoimmune diseases, yet its financial outlook appears challenged due to several persistent issues. High levels of thyroid stimulating hormone receptor antibodies (TRAbs) are correlated with increased relapse rates and complications, which may hinder the clinical success of its drug candidate and affect market adoption. Additionally, the potential for serious complications, such as inflammation that can compress the optic nerve, raises concerns regarding the overall viability and safety profile of Immunovant's treatment approaches, potentially impacting investor confidence and future revenues.
This aggregate rating is based on analysts' research of Immunovant Inc and is not a guaranteed prediction by Public.com or investment advice.
Immunovant Inc (IMVT) Analyst Forecast & Price Prediction
Start investing in Immunovant Inc (IMVT)
Order type
Buy in
Order amount
Est. shares
0 shares